Gekeler Katrin, Bartz-Schmidt Karl Ulrich, Sachs Helmut, MacLaren Robert E, Stingl Katarina, Zrenner Eberhart, Gekeler Florian
Department of Ophthalmology, Katharinenhospital, Klinikum Stuttgart, Stuttgart.
Centre for Ophthalmology, Eberhard-Karls-University, Tübingen.
Curr Opin Ophthalmol. 2018 May;29(3):239-247. doi: 10.1097/ICU.0000000000000467.
The purpose of this review is to provide an update on the efforts to restore vision through subretinal implants in patients with degenerative retinal diseases. In addition to the current technique and its latest improvements, it will focus on the surgical technique of implantation as well as explantation and reimplantation.
The durability of the current subretinal implant RETINA IMPLANT Alpha AMS has increased substantially compared with the predecessor model RETINA IMPLANT Alpha IMS. According to validated examinations in the laboratory, a median lifetime of 4.7 years will be reached in clinical use; in similar examinations, the previous model has reached only 8 months. Visual function has slightly increased. The surgical technique for subretinal implants is complex and demanding for ophthalmic surgeons, as it is multifaceted and combines novel surgical steps in areas, which are not commonly entered such as the suprachoroidal and the subretinal space. The surgical approach for implantation has matured considerably and has led to successful implantation in 64 patient cases. Surgical challenges are now mainly encountered with the exact subfoveal positioning of the device. The explantation procedure is relatively straight-forward because the implant can be withdrawn in a reverse direction along the already existent subretinal path. Reimplantations, however, are more challenging because some degree of scar tissue may exist along the path of the chip and around the scleral trapdoor. Nevertheless, reimplantations have now been carried out successfully in four patients.
The new RETINA IMPLANT Alpha AMS shows significantly improved durability compared with the predecessor model RETINA IMPLANT Alpha IMS. The subretinal implant offers excellent visual results but requires experienced surgeons. Explantation of devices is straight-forward, and reimplantations are challenging but have been successful in four patients.
本综述旨在提供有关通过视网膜下植入物恢复退行性视网膜疾病患者视力的最新进展。除了当前技术及其最新改进外,还将重点关注植入手术技术以及取出和重新植入技术。
与前代产品RETINA IMPLANT Alpha IMS相比,当前视网膜下植入物RETINA IMPLANT Alpha AMS的耐用性有了显著提高。根据实验室的验证检查,临床使用中该植入物的中位使用寿命将达到4.7年;在类似检查中,前代产品仅达到8个月。视觉功能略有提高。视网膜下植入物的手术技术复杂,对眼科医生要求较高,因为它涉及多方面,并且在诸如脉络膜上腔和视网膜下间隙等不常进入的区域结合了新的手术步骤。植入手术方法已经相当成熟,已在64例患者中成功植入。目前手术的挑战主要在于设备在黄斑中心凹下的确切定位。取出手术相对简单,因为植入物可以沿着已有的视网膜下路径反向取出。然而,重新植入更具挑战性,因为芯片路径和巩膜活瓣周围可能存在一定程度的瘢痕组织。尽管如此,目前已有4例患者成功进行了重新植入。
新型RETINA IMPLANT Alpha AMS与前代产品RETINA IMPLANT Alpha IMS相比,耐用性有显著提高。视网膜下植入物可提供出色的视觉效果,但需要经验丰富的外科医生。设备取出简单,重新植入具有挑战性,但已有4例患者成功进行了重新植入。